Here's why the Sonic Healthcare share price (ASX:SHL) is up 9% in December

Sonic Healthcare is having a positive month as COVID-19 cases and demand for testing surges.

| More on:
A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Sonic Healthcare Limited (ASX: SHL) share price is having a bright December, capping off a bumper year.

Shares in the medical diagnostic company are swapping hands at $46.49 at the time of writing, up 8.88% for the month.

Let's take a look at what might be driving this recent investor confidence in Sonic Healthcare.

A merry December for Sonic Healthcare

The Sonic Healthcare share price has been climbing steadily despite no price-sensitive announcements from the company this month.

It did deliver some positive news on 17 December, though. Sonic Healthcare announced it has acquired ProPath, an anatomical pathology company based in Dallas, Texas in the United States.

ProPath will bring additional annual revenue of about $110 million to Sonic Healthcare, along with 50 pathologist staff. The takeover was part of Sonic's wider plan to combine anatomical pathology and clinical laboratory testing in the US.

Sonic Healthcare's soaring share price has coincided with a rise in demand for COVID-19 testing and vaccinations in December.

Sonic Healthcare is Australia's largest private pathology operator with global operations all over the world, including Germany, Switzerland, the UK, Belgium, New Zealand, and the US.

The company tests thousands of people each day for COVID-19 and is also involved in the Australian vaccination program.

Demand for COVID-19 testing for travel has also been on the rise this month. Sonic offers a COVID-19 PCR test for international travel at a cost of $145 per test per person.

Sonic Healthcare is likely on investors' minds this month due to surging COVID-19 cases and increased demand for testing.

Federal Health Minister Greg Hunt has announced that the minimum interval between COVID-19 double vaccination and booster shots will be reduced to 4 months from 4 January.

A national cabinet agreement to shift the focus to Rapid Antigen Tests (RAT) and redefine the term 'close contact' could impact PCR testing demand.

Sonic Healthcare share price recap

The Sonic Healthcare share price has soared 44% in the past 12 months and has climbed 1.24% in the past week.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 14% in the past year.

The company has a market capitalisation of more than $22 billion based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »